Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement

Emirates PharmaAdvertisement

Bristol-Myers Squibb Company announced it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb’s CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche’s investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma. Under the agreement, the two companies will conduct a Phase I/II study to evaluate the safety and efficacy of the combination. If appropriate, the companies may conduct further development of the combination. This agreement represents an important cross-company collaboration exploring the potential role of this regimen in the treatment of metastatic melanoma.

Brian Daniels, senior vice president, Development and Medical Affairs, Bristol-Myers Squibb said, Metastatic melanoma is one of the most aggressive forms of cancer. We are excited to be working with Roche to evaluate the potential that together YERVOY and vemurafenib could improve outcomes for melanoma patients.

Emirates PharmaAdvertisement